Enterprise Value
211.2M
Cash
93.41M
Avg Qtr Burn
-20.85M
Short % of Float
2.42%
Insider Ownership
0.66%
Institutional Own.
58.56%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Mavorixafor (CXCR4 inhibitor) Details WHIM Syndrome | NDA Submission | |
Mavorixafor (CXCR4 inhibitor) Details Severe Congenital Neutropenia | Phase 2 Data readout | |
Mavorixafor (CXCR4 inhibitor) + ibrutinib Details Waldenstrom macroglobulinemia | Failed Discontinued | |
Mavorixafor (CXCR4 inhibitor) Details Renal cell carcinoma, Cancer | Failed Discontinued |